Keros Therapeutics, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Keros Therapeutics, Inc. | KROS - NASDAQ |
Last trade $41.26 |
$40.00 |
$0.00 | 3.5 million | 1/4/2024 |
Goldman Sachs, Leerink, Piper Sandler, Truist |
Co-Manager(s): |
Health Care |
Filing(s): |
For IPO Boutique's "scale of 1 to 5" BUY rating on Keros Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".
Keros Therapeutics, Inc. Quote & Chart - Click for current quote -
KROS
About Keros Therapeutics, Inc. (adapted from Keros Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "KROS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved